Safety and efficacy of delayed release rabeprazole in 1-to 11-month-old infants with symptomatic GERD

Journal of Pediatric Gastroenterology and Nutrition

Volumn 58, Issue 2, 2014, Pages 226-236

  Hussain, Sunny ^a   Kierkus, Jaroslaw ^b   Hu, Peter ^c   Hoffman, Diane ^c   Lekich, Ray ^c   Sloan, Sheldon ^c   Treem, William ^c  

^a WK Pediatric Gastroenterology and Research   (United States)

^b CHILDREN'S MEMORIAL HEALTH INSTITUTE   (Poland)

^c JANSSEN RESEARCH AND DEVELOPMENT   (United States)

Author keywords

delayed release; gastroesophageal reflux disease; infants; rabeprazole

Indexed keywords

PROTON PUMP INHIBITOR; RABEPRAZOLE;

BODY WEIGHT; COMPLICATION; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECTS; GASTROESOPHAGEAL REFLUX; HUMAN; INFANT; MALE; NEWBORN; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; VOMITING;

BODY WEIGHT; DOUBLE-BLIND METHOD; GASTROESOPHAGEAL REFLUX; HUMANS; INFANT; INFANT, NEWBORN; MALE; PROTON PUMP INHIBITORS; QUESTIONNAIRES; RABEPRAZOLE; TREATMENT OUTCOME; VOMITING;

EID: 84894077891     PISSN: 02772116     EISSN: 15364801     Source Type: Journal    
DOI: 10.1097/MPG.0000000000000195     Document Type: Article

References (37)

1. Orenstein SR, Shalaby TM, Devandry SN, et al. Famotidine for infant gastro-oesophageal reflux: a multi-centre, randomized, placebo-controlled, withdrawal trial. Aliment Pharmacol Ther 2003;17:1097-107.
2. Vandenplas Y, Rudolph CD, Di Lorenzo C, et al. Pediatric gastroeso-phageal reflux clinical practice guidelines: joint recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN) and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN). J Pediatr Gastroenterol Nutr 2009;49:498-547.
3. Gold BD, Freston JW. Gastroesophageal reflux in children: pathogen-esis, prevalence, diagnosis, and role of proton pump inhibitors in treatment. Paediatr Drugs 2002;4:673-85.
4. Furuta GT, Liacouras CA, Collins MH, et al. Eosinophilic esophagitis in children and adults: a systematic review and consensus recommendations for diagnosis and treatment. Gastroenterology 2007;133:1342-63.
5. Gremse DA. GERD in the pediatric patient: management considerations. Med Gen Med 2004;6:13.
6. Tolia V, Youssef NN, Gilger MA, et al. Esomeprazole for the treatment of erosive esophagitis in children: an international, multicenter, randomized, parallel-group, double-blind (for dose) study. BMC Pediatr 2010;10:41.
7. Franco MT, Salvia G, Terrin G, et al. Lansoprazole in the treatment of gastro-oesophageal reflux disease in childhood. Dig Liver Dis 2000; 32:660-6.
8. Hassall E, Israel D, Shepherd R, et al. Omeprazole for treatment of chronic erosive esophagitis in children: a multicenter study of efficacy, safety, tolerability and dose requirements. International Pediatric Ome-prazole Study Group. J Pediatr 2000;137:800-7.
9. Nexium [package insert]. Wilmington, DE: AstraZeneca; 2012.
10. Omari T, Davidson G, Bondarov P, et al. Pharmacokinetics and acid-suppressive effects of esomeprazole in infants 1-24 months old with symptoms of gastroesophageal reflux disease. J Pediatr Gastroenterol Nutr 2007;45:530-7.
11. van der Pol RJ, Smits MJ, van Wijk MP, et al. Efficacy of proton-pump inhibitors in children with gastroesophageal reflux disease: a systematic review. Pediatrics 2011;127:925-35.
12. Chen IL, Gao WY, Johnson AP, et al. Proton pump inhibitor use in infants: FDA reviewer experience. J Pediatr Gastroenterol Nutr 2012; 54:8-14.
13. Aciphex [package insert]. Tokyo, Japan: Eisai Company Ltd; 2007.
14. Leitz GJ, Ibrahim H, Tron E, et al. A multi-center, double-blind, parallel-group study to evaluate short-term safety and efficacy and long-term maintenance of two dose levels of rabeprazole sodium delayed-release pediatric bead formulation in 1 to 11 year-old pediatric subjects with endoscopically proven GERD. Gastroenterology 2011; 140 (suppl 1):S579.
15. Kleinman L, Rothman M, Strauss R, et al. The infant gastroesophageal reflux questionnaire revised: development and validation as an evaluative instrument. Clin Gastroenterol Hepatol 2006;4:588-96.
16. Zannikos PN, Doose DR, Leitz GJ, et al. Pharmacokinetics and toler-ability of rabeprazole in children 1 to 11 years old with gastroesophageal reflux disease. J Pediatr Gastroenterol Nutr 2011;52:691-701.
17. Pace F, Pallotta S, Casalini S, et al. A review of rabeprazole in the treatment of acid-related diseases. Ther Clin Risk Manag 2007;3:363-79.
18. Thyssen A, Solanki B, Treem W. Randomized, open-label, single-dose, crossover, relative bioavailability study in healthy adults, comparing the pharmacokinetics of rabeprazole granules administered using soft food or infant formula as dosing vehicle versus suspension. Clin Ther 2012;34:1636-45.
19. Winter H, Gunasekaran T, Tolia V, et al. Esomeprazole for the treatment of GERD in infants ages 1-11 months. J Pediatr Gastroenterol Nutr 2012;55:14-20.
20. Moore DJ, Tao BS, Lines DR, et al. Double-blind placebo-controlled trial of omeprazole in irritable infants with gastroesophageal reflux. J Pediatr 2003;143:219-23.
21. Orenstein SR, Hassall E, Furmaga-Jablonska W, et al. Multicenter, double-blind, randomized, placebo-controlled trial assessing the efficacy and safety of proton pump inhibitor lansoprazole in infants with symptoms of gastroesophageal reflux disease. J Pediatr 2009;154:514-20e514.
22. Khoshoo V, Dhume P. Clinical response to 2 dosing regimens of lansoprazole in infants with gastroesophageal reflux. J Pediatr Gastro-enterol Nutr 2008;46:352-4.
23. Winter H, Kum-Nji P, Mahomedy SH, et al. Efficacy and safety of pantoprazole delayed-release granules for oral suspension in a placebo-controlled treatment-withdrawal study in infants 1-11 months old with symptomatic GERD. J Pediatr Gastroenterol Nutr 2010;50:609-18.
24. 2010 Meeting Materials GDAC. Gaithersburg, MD; November 5, 2010.
25. Nelson SP, Chen EH, Syniar GM, et al. One-year follow-up of symptoms of gastroesophageal reflux during infancy. Pediatric Practice Research Group. Pediatrics 1998;102:E67.
26. Francavilla R, Magista AM, Bucci N, et al. Comparison of esophageal pH and multichannel intraluminal impedance testing in pediatric patients with suspected gastroesophageal reflux. J Pediatr Gastroenterol Nutr 2010;50:154-60.
27. Orenstein SR, Hassall E. Infants and proton pump inhibitors: tribulations, no trials. J Pediatr Gastroenterol Nutr 2007;45:395-8.
28. Irvine EJ, Whitehead WE, Chey WD, et al. Design of treatment trials for functional gastrointestinal disorders. Gastroenterology 2006;130:1538-51.
29. Gilger MA, El-Serag HB, Gold BD, et al. Prevalence of endoscopic findings of erosive esophagitis in children: a population-based study. J Pediatr Gastroenterol Nutr 2008;47:141-6.
30. Franciosi JP, Fiorino K, Ruchelli E, et al. Changing indications for upper endoscopy in children during a 20-year period. J Pediatr Gastroenterol Nutr 2010;51:443-7.
31. McCarthy DM. Adverse effects of proton pump inhibitor drugs: clues and conclusions. Curr Opin Gastroenterol 2010;26:624-31.
32. Hoorn EJ, van der Hoek J, de Man RA, et al. A case series of proton pump inhibitor-induced hypomagnesemia. Am J Kidney Dis 2010; 56:112-6.
33. Turco R, Martinelli M, Miele E, et al. Proton pump inhibitors as a risk factor for paediatric Clostridium difficile infection. Aliment Pharmacol Ther 2010;31:754-9.
34. Canani RB, Cirillo P, Roggero P, et al. Therapy with gastric acidity inhibitors increases the risk of acute gastroenteritis and community-acquired pneumonia in children. Pediatrics 2006;117:e817-20.
35. Guillet R, Stoll BJ, Cotten CM, et al. Association of H2-blocker therapy and higher incidence of necrotizing enterocolitis in very low birth weight infants. Pediatrics 2006;117:e137-42.
36. Hassall E, Shepherd R, Koletzko S, et al. Long-term maintenance treatment with omeprazole in children with healed erosive oesophagitis: a prospective study. Aliment Pharmacol Ther 2012;35:368-79.
37. Madrazo-de la Garza A, Dibildox M, Vargas A, et al. Efficacy and safety of oral pantoprazole 20 mg given once daily for reflux esophagitis in children. J Pediatr Gastroenterol Nutr 2003;36:261-5.